Ligand Pharmaceuticals, Inc’s recently made public that its Director KOZARICH JOHN W unloaded Company’s shares for reported $61586.0 on Aug 01 ’25. In the deal valued at $131.88 per share,467 shares were sold. As a result of this transaction, KOZARICH JOHN W now holds 45,989 shares worth roughly $7.02 million.
Then, KOZARICH JOHN W bought 467 shares, generating $61,177 in total proceeds.
Before that, KOZARICH JOHN W sold 934 shares. Ligand Pharmaceuticals, Inc shares valued at $116,750 were divested by the Director at a price of $125.00 per share. As a result of the transaction, KOZARICH JOHN W now holds 46,456 shares, worth roughly $7.09 million.
Stifel initiated its Ligand Pharmaceuticals, Inc [LGND] rating to a Buy in a research note published on April 10, 2025; the price target was $143. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early October with a ‘”an Outperform”‘ rating. RBC Capital Mkts began covering LGND with “an Outperform” recommendation on July 30, 2024.
Price Performance Review of LGND
On Tuesday, Ligand Pharmaceuticals, Inc [NASDAQ:LGND] saw its stock jump 3.86% to $152.69. Over the last five days, the stock has gained 12.98%. Ligand Pharmaceuticals, Inc shares have risen nearly 57.54% since the year began. Nevertheless, the stocks have risen 42.50% over the past one year. While a 52-week high of $151.55 was reached on 08/12/25, a 52-week low of $93.58 was recorded on 04/09/25.
Levels Of Support And Resistance For LGND Stock
The 24-hour chart illustrates a support level at 148.95, which if violated will result in even more drops to 145.21. On the upside, there is a resistance level at 156.48. A further resistance level may holdings at 160.27.
How much short interest is there in Ligand Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Ligand Pharmaceuticals, Inc stocks on 2025-07-31, dropping by -0.27 million shares to a total of 0.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 1.19 million shares. There was a decline of -29.69%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 04, 2021 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $310.
